title: [Evaluation of thiazolidinedione derivative drugs for safety].
abstract: The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial. Subsequently, pioglitazone has been clinically used both in Japan and U.S. and has had no fatal cases but caused heart failure. Therefore, careful follow up observation is necessary in these drugs by checking liver function tests and cardiac function.
authors.affiliation: First Department of Internal Medicine, Toyama Medical & Pharmaceutical University.
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Iwata
mesh_terms: D000818:Animals; D056486:Chemical and Drug Induced Liver Injury; D002839:Chromans / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004487:Edema / Q000139:chemically induced; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D000077205:Pioglitazone; D013844:Thiazoles / Q000009:adverse effects*; D045162:Thiazolidinediones; D000077288:Troglitazone
chemical_list: D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione; D000077288:Troglitazone; D000077205:Pioglitazone